Junshi Biosciences Back in the Red, Pins Hopes on Covid Drugs
The innovative drug developer reported a first-quarter loss as a result of a steep drop in licensing revenue Key Takeaways: Junshi Biosciences’ revenue tumbled 61% in the first quarter, reflecting…
Recent Articles
RELATED ARTICLES
-
Will Junshi Bio’s loss-making headaches ease with landmark U.S. drug approval?
1877.HK 688180.SHG -
Junshi hopes new scientist CEO can cure its woes
1877.HK 688180.SHG
-
HBM gets health boost from drug licensing deals
2142.HK
-
Akeso marks profit milestone with swift rights issue
9926.HK
